Pninit Litman

Subcellular localization of tau mRNA in differentiating neuronal cell culture: Implications for neuronal polarity

A primary neuronal cell culture derived from whole brains of fetal rats was used to analyze the subcellular localization of tau mRNA, employing nonisotopic detection by in situ hybridization. The culture exhibited a developmental differentiation pattern previously described for neuronal cells in vivo; i.e., a transition from immature to mature tau isoforms as well as segregation of tau into the axons. Our results demonstrate that unlike tubulin mRNA, which is confined to cell bodies, or MAP2 mRNA, which extends into dendrites, tau mRNA was observed to enter the proximal portion of the axon. This sorting of tau mRNA might explain how the tau protein could be selectively delivered to the axon and could have important implications for the development of neuronal polarity.

Microtubules are involved in the localization of tau mRNA in primary neuronal cell cultures

Subcellular localization of neuronal mRNAs contributes to the development of identifiable microdomains. In differentiated neurons, tau mRNA is localized in the cell body and the proximal portion of the axon, and MAP2 mRNA is localized in the cell body and dendrites, whereas tubulin mRNA is restricted to the cell body. To investigate the mechanism(s) leading to segregation of mictrotubule-associated protein mRNA, we examined the role of the cytoskeleton in this process. Detergent extraction of primary neuronal cells in culture followed by in situ hybridization analysis demonstrated that tau mRNA remains bound to cytoskeleton of the treated cells. In addition, biochemical fractionation showed that tau and MAP2 mRNAs are preferentially associated with the fraction of assembled microtubules. In contrast, mRNAs restricted to the neuronal cell body, such as those of tubulin, the 68 kDa neurofilament, and mouse GAPDH, are preferentially found in the supernatant. Using cytoskeletal inhibitors, we demonstrate that tau mRNA is associated with the microtubule system, and not with the actin filaments, thus supporting the hypothesis that the mechanism of mRNA localization is a multistep pathway in which the microtubules play a crucial role.

Human Somatostatin Receptor Specificity of Backbone-Cyclic Analogues Containing Novel Sulfur Building Units

Somatostatin-14 (somatostatin) and its clinically available analogues octreotide, lanreotide, and vapreotide are potent inhibitors of growth hormone, insulin, and glucagon release. Recently, a novel backbone cyclic somatostatin analogue c(GABA-Phe-Trp-(D)Trp-Lys-Thr-Phe-GlyC3-NH(2)) (analogue 1, PTR 3173) that possesses in vivo endocrine selectivity was described. This long-acting octapeptide exhibits high affinity to human recombinant somatostatin receptors (hsst) hsst2, hsst4, and hsst5. Its novel binding profile resulted in potent in vivo inhibition of growth hormone but not of insulin release. We report the synthesis, bioactivity, and structure-activity relationship studies of compounds related to 1. In these analogues, the lactam bridge of 1 was replaced by a backbone disulfide bridge. We present a novel approach for conformational constraint of peptides by utilizing sulfur-containing building units for on-resin backbone cyclization. These disulfide backbone cyclic analogues of 1 showed significant metabolic stability as tested in various enzyme mixtures. Receptor binding assays revealed different receptor selectivity profiles for these analogues in comparison to their prototype. It was found that analogues of 1, bearing a disulfide bridge, had increased selectivity to hsst2 and hsst5; however, they exhibited weaker affinity to hsst4 as compared to 1. These studies imply that ring chemistry, ring size, and ring position of the peptide template may affect the receptor binding selectivity.